Enzyvant Sciences

What Enzyvant Sciences does

Enzyvant Sciences is a clinical-stage biotechnology company focused on developing cell and gene therapies for rare diseases. Founded in 2016 and headquartered in Basel, Switzerland, the company operates in the cell and gene therapy (CGT) sector, where approximately 4,099 therapies are reportedly in development industry-wide and 51% of newly initiated gene therapy trials target non-oncology indications. Enzyvant was recognized among 100 Cell and Gene Therapy Leaders to Watch in 2025, an evaluation based on FDA-approved products, clinical pipeline stage, patent activity, strategic partnerships, and funding milestones.

The company's core technology is described as a cell and gene therapy development platform, though specific proprietary features, scientific platform architecture, and pipeline assets are not publicly disclosed in available sources. Enzyvant operates with a lean team of 11-50 employees, consistent with an early-stage development model reliant on specialized scientific talent rather than large-scale operations. No patents, trademark registrations, regulatory designations, or named partnerships are disclosed in the available data.

Enzyvant's business model is pre-commercial: the company has no FDA-approved products, no disclosed revenue, no public pricing structure, and no established distribution channels. Revenue mechanics would only materialize upon regulatory approval of therapeutic candidates. Commercial pricing and distribution would be established post-approval. As a private company founded in 2016 with no disclosed funding rounds, ownership structure, or named investors in the available source material, the firm's capital base and runway are not verifiable from public data.

Name

Enzyvant Sciences

Website

https://enzyvant.com

Company type

Private

Founded year

2016

Headcount range

11–50 employees

Short description

Enzyvant Sciences is a clinical-stage biotechnology company founded in 2016 and headquartered in Basel, Switzerland, focused on developing cell and gene therapies for rare diseases. The firm operates with 11-50 employees and has no approved products.

Ownership category

akta.pro rank

Product category

Cell and Gene Therapy for Rare Diseases

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)

Keywords

• Rare disease therapies
• Cell and gene therapy
• Biopharmaceutical development
• Clinical stage biotechnology
• Genetic medicines

Headquarters

HQ city

Basel

HQ country

Switzerland

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Core offering

Enzyvant Sciences is a clinical-stage biopharmaceutical company developing cell and gene therapies for rare diseases. The company operates within the broader cell and gene therapy sector, building a pipeline of therapeutic candidates aimed at addressing unmet medical needs in rare disease populations. Its activities focus on preclinical and clinical development of advanced therapy candidates rather than commercial-stage product sales.

Product overview

Enzyvant Sciences is a biopharmaceutical company focused on developing cell and gene therapies for rare diseases. The company operates in the cell and gene therapy (CGT) sector, with a development pipeline targeting unmet medical needs. Based on the source material, Enzyvant Sciences is identified among 100 leading cell and gene therapy organizations to watch in 2025, evaluated on FDA-approved products, clinical pipeline stage, patent activity, strategic partnerships, and funding milestones.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves2 records

Expansion highlights1 record

Direct peers

• Bluebird Bio: Clinical-stage gene therapy company developing treatments for severe genetic and rare diseases. Highly comparable to Enzyvant given shared focus on cell and gene therapies targeting rare/monogenic conditions with similar regulatory and manufacturing challenges.
• Sarepta Therapeutics: Commercial-stage gene therapy company specializing in rare neuromuscular diseases. Directly comparable as a CGT-focused rare disease specialist with both approved products and active pipeline development.
• BioMarin Pharmaceutical: Commercial biopharmaceutical company focused on rare diseases, including gene therapy products. Comparable in rare disease specialization, with overlapping therapeutic areas and similar regulatory pathways for orphan drug development.
• Ultragenyx Pharmaceutical: Clinical and commercial-stage rare disease biopharmaceutical company developing novel therapies including gene therapies. Comparable in rare disease specialization and pipeline approach, with parallel gene therapy development programs.
• Spark Therapeutics (Roche): Gene therapy company (now part of Roche) that pioneered approved AAV-based gene therapies for rare inherited diseases. Highly comparable in CGT modality and rare disease focus, with established commercial gene therapy experience.
• uniQure: Gene therapy company developing AAV-based treatments for rare diseases including hemophilia and Huntington's disease. Closely comparable in modality, therapeutic focus, and development stage as a clinical-stage gene therapy specialist.
• Regenxbio: Clinical-stage gene therapy company developing AAV therapeutics for rare diseases including wet AMD and Duchenne muscular dystrophy. Comparable in gene therapy modality, rare disease focus, and partnership-driven commercialization strategy.

Broad incumbents

• AveXis (Novartis): Gene therapy subsidiary of Novartis focused on rare diseases, including the SMA gene therapy Zolgensma. Comparable in CGT rare disease focus, with greater scale and resources as part of a global pharmaceutical leader.
• BridgeBio Pharma: Commercial-stage biopharmaceutical company focused on genetic diseases and rare conditions. Comparable in rare disease specialization with broader pipeline diversification across multiple therapeutic areas.

Emerging players

• Voyager Therapeutics: Clinical-stage gene therapy company developing AAV-based treatments for neurological diseases. Comparable in gene therapy platform approach and rare disease focus, though at smaller scale and earlier development stage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

• Xx.com/Enzyvant

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enzyvant Sciences